Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes
Research output: Contribution to journal › Journal article › Research › peer-review
Dipeptidyl peptidase-4 (DPP-4) inhibitors block the degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. The aim of the present study was to quantitatively assess the incretin effect after treatment with the DPP-4 inhibitor vildagliptin (V) or placebo (P) in patients with type 2 diabetes.
| Original language | English |
|---|---|
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Volume | 96 |
| Issue number | 4 |
| Pages (from-to) | 945-954 |
| Number of pages | 10 |
| ISSN | 0021-972X |
| DOIs | |
| Publication status | Published - 2011 |
- Adamantane, Administration, Oral, Adult, Aged, Blood Glucose, Cross-Over Studies, Diabetes Mellitus, Type 2, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Female, Glucose, Humans, Incretins, Injections, Intravenous, Insulin, Male, Middle Aged, Nitriles, Pyrrolidines, Up-Regulation
Research areas
ID: 38444411